Physician profile
Jay A Goldstein
NPI 1851483762
$3,492.24
in general payments reported to CMS, 2019-2025
20 companies · $899 in 2025
The $899 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $114 · 2021: $171 · 2022: $634 · 2023: $625 · 2024: $804 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.33 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.54 | 2019-2025 | |
| Janssen Biotech, INC. | $381.80 | 2019-2025 | Tremfya |
| Ucb, INC. | $284.89 | 2023-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $283.05 | 2023-2025 | Sotyktu |
| Pfizer INC. | $261.11 | 2019-2025 | |
| Merz North America, INC. | $246.21 | 2022 | |
| Lilly USA, LLC | $215.34 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Amgen INC. | $175.49 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $174.83 | 2020-2022 | |
| Revance Therapeutics, INC. | $158.94 | 2024 | Daxxify |
| Galderma Laboratories, L.P. | $93.94 | 2022-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $84.76 | 2019-2023 | Libtayo |
| Incyte Corporation | $65.67 | 2023-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $64.68 | 2021-2022 | |
| Dermavant Sciences, INC. | $45.02 | 2023 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $37.11 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.65 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.29 | 2024 | Clear+Brilliant |
| Celgene Corporation | $23.78 | 2019 | |
| Genzyme Corporation | $20.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.